UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000018041 |
|---|---|
| Receipt number | R000020896 |
| Scientific Title | The Efficacy of 0.01% Atropine Ophthalmic Solution for Controlling the Progression of Childhood Myopia (ATOM-J Study) |
| Date of disclosure of the study information | 2015/06/23 |
| Last modified on | 2018/12/26 19:17:37 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The Efficacy of 0.01% Atropine Ophthalmic Solution for Controlling the Progression of Childhood Myopia (ATOM-J Study)
Acronym
The Efficacy of 0.01% Atropine Ophthalmic Solution for Controlling the Progression of Childhood Myopia (ATOM-J Study)
Scientific Title
The Efficacy of 0.01% Atropine Ophthalmic Solution for Controlling the Progression of Childhood Myopia (ATOM-J Study)
Scientific Title:Acronym
The Efficacy of 0.01% Atropine Ophthalmic Solution for Controlling the Progression of Childhood Myopia (ATOM-J Study)
Region
| Japan |
Condition
Condition
Mild or moderate myopia
Classification by specialty
| Ophthalmology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The objective of this study is to verify the safety and the ability to control the progression of myopia of 0.01% atropine ophthalmic solution in Japanese children diagnosed with mild or moderate myopia
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Change from baseline in objective spherical equivalent at the end of 24 months of drug treatment.
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
0.01% atropine ophthalmic solution
Interventions/Control_2
Placebo ophthalmic solution
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 6 | years-old | <= |
Age-upper limit
| 12 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
(1) Male or female children aged 6 -to 12 years (elementary school grades 1-6) at the time of consent
(2) Children with a decrease in visual acuity in the vision assessment in a school physical examination within the past year.
(3) Children with a cycloplegic objective spherical equivalent of -1.00D to-6.00D in each eye
(4) Children with anisometropia within 1.50D.
(5) Children with astigmatism within +/- 1.50D
(6) Children with corrected visual acuity of at least 1.0
(7) Children with no intraocular pressure abnormalities
(8) Children capable of undergoing cycloplegia
(9) Children who can undergo outpatient examinations per protocol
(10) Written informed consent to participate in the study obtained from the child personally and from a person with parental authority
Key exclusion criteria
(1) Children with abnormal visual function bilaterally
(2) Children with amblyopia or manifest strabismus
(3) Children with difference in objective spherical equivalent with and without cycloplegia of more than 1.00D in each eye
(4) Children with ocular disorders other than myopia
(5) Children with ocular or systemic disorders that potentially affect myopia or refractive power
(6) Children who have received previous treatment for myopia that included atropine therapy such as contact lenses, bifocal lenses, or progressive lenses with atropine therapy (however, this does not apply to children who discontinued 0.4% tropicamide ophthalmic solution at least 3 months previously)
(7) Children with a history of cardiovascular or respiratory disease
(8) Children who have received pharmacotherapy for asthma in the past year
(9) Children with a history of allergy to atropine, cyclopentolate, or benzalkonium
(10) Children who cannot instill medication into the eye
(11) Children who may require contact lenses, bifocal lenses, or progressive lenses during the clinical study period
(12) Children deemed otherwise unsuitable for the study by the (sub)investigator
Target sample size
180
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Shigeru Kinoshita,M.D.,Ph.D. |
Organization
Kyoto Prefectural University of Medicine
Division name
Department of Frontier Medical Science and Technology for Ophtalmology
Zip code
Address
465 Kajiicho, Hirokoji agaru, Kawaramachi-dori Street, Kamigyo-ku Ward, Kyoto City, Kyoto, Japan
TEL
+81-75-251-5578
shigeruk@koto.kpu-m.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Atropine for Childhood Myopia study secretariat |
Organization
Satt Co., Ltd.
Division name
Clinical Research Group
Zip code
Address
5F, ACN Shinjuku Bldg. 2-12-8 Shinjuku, Shinjuku-ku, Tokyo 160-0022,Japan
TEL
+81-3-5312-5026
Homepage URL
atropine@sa-tt.co.jp
Sponsor or person
Institute
Kyoto Prefectural University of Medicine
Institute
Department
Personal name
Funding Source
Organization
Japanese Research Center of Refractive Surgery
Organization
Division
Category of Funding Organization
Non profit foundation
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
京都府立医科大学病院（京都）
慶應義塾大学病院（東京都）
旭川医科大学病院（北海道）
大阪大学医学部附属病院（大阪府）
川崎医科大学総合医療センター（岡山県）
筑波大学附属病院（茨城県）
日本医科大学付属病院（東京都）
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 06 | Month | 23 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2015 | Year | 04 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2015 | Year | 07 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2015 | Year | 06 | Month | 23 | Day |
Last modified on
| 2018 | Year | 12 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020896
